Pneumococcal Conjugate Vaccine (PCV) for elderly adults 60 years old and above

HTA Council Preliminary Recommendation (as of  27 March 2026) As a final recommendation, the HTA Council recommends the government financing of pneumococcal polysaccharide vaccine (PPSV23) for all adults 60 years old and above. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page

Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y

HTA Council Recommendation (as of 10 February 2026) As a final recommendation, the HTA Council recommends the government financing of the Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for individuals from the age of 6 weeks (pediatric population) and populations at high-risk for invasive diseases*, with priority for:  *population at high-risk for continue reading : Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y

Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas

HTA Council Recommendation (as of 13 June 2025) The HTA Council positively recommends the government financing of  both live, attenuated, recombinant, vero cell; and, inactivated adsorbed, vero cell Japanese Encephalitis vaccines to be rolled out in high risk areas (as defined by DOH), contingent on the budget and resource availability. (See below for more details) continue reading : Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas

Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization

HTA Council Recommendation (as of 16 May 2025) The HTA Council positively recommends the government financing of the following PCVs for infants less than 1 year old and children aged 13 to 23 months, in no particular order: Recommending the above-mentioned vaccines will provide the National Immunization Program (NIP) more options and more flexibility in continue reading : Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization